ST Pharm Co.,Ltd. (KOSDAQ:237690)
118,000
+100 (0.08%)
At close: Dec 5, 2025
ST Pharm Revenue
ST Pharm had revenue of 81.91B KRW in the quarter ending September 30, 2025, with 32.75% growth. This brings the company's revenue in the last twelve months to 318.32B, up 14.24% year-over-year. In the year 2024, ST Pharm had annual revenue of 273.75B, down -3.94%.
Revenue (ttm)
318.32B
Revenue Growth
+14.24%
P/S Ratio
7.67
Revenue / Employee
485.98M
Employees
655
Market Cap
2,442.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 273.75B | -11.24B | -3.94% |
| Dec 31, 2023 | 284.99B | 35.67B | 14.31% |
| Dec 31, 2022 | 249.32B | 83.68B | 50.52% |
| Dec 31, 2021 | 165.64B | 41.53B | 33.47% |
| Dec 31, 2020 | 124.11B | 30.85B | 33.08% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,504.84B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| ABL Bio | 88.44B |
| SK Biopharmaceuticals | 675.41B |
| Yuhan | 2,136.67B |
| LigaChem Biosciences | 159.27B |
| Peptron | 6.19B |